Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies

Dario Venetz1, Christian Hess1, Chia-wei Lin2

  • 1Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, and.

Insights

Antibody extravasation is key for cancer therapy. This study found that specific N-linked glycan structures on antibodies significantly impact tumor targeting efficiency, emphasizing glycosylation control in drug development.

Area of Science:

  • Biotechnology
  • Immunology
  • Glycobiology

Background:

  • Antibody extravasation is crucial for reaching molecular targets in diseases, as these targets are often located outside blood vessels.
  • Understanding the factors influencing antibody biodistribution is essential for developing effective antibody-based therapeutics.

Purpose of the Study:

  • To investigate the correlation between N-linked glycan structures and the tumor-targeting efficiency of a novel IL9-armed cancer-specific antibody.
  • To analyze the glycan microheterogeneity on the IL9 portion of the recombinant antibody.
  • To determine the impact of specific glycan structures on antibody homing activity.

Main Methods:

  • Detailed biodistribution studies were performed using a novel IL9-armed cancer-specific antibody.
  • Site-specific glycan analysis was employed to characterize the N-linked glycan structures.
  • Correlation analysis was conducted between glycan structures and tumor-targeting efficiencies.

Main Results:

  • A clear correlation was identified between N-linked glycan structures and tumor-targeting efficiencies.
  • Site-specific glycan analysis revealed significant glycan microheterogeneity on the IL9 portion of the antibody.
  • Nonsialylated glycan structures were found to negatively impact disease-homing activity.

Conclusions:

  • N-linked glycan structure is a critical determinant of antibody tumor-targeting efficiency.
  • Glycosylation control and thorough characterization are vital during the process development of antibody-based therapeutics.
  • Minimizing nonsialylated glycans may enhance the therapeutic efficacy of antibodies by improving disease homing.

Related Concept Videos

Proteoglycans01:05

Proteoglycans

Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
5.3K
Oligosaccharide Assembly01:24

Oligosaccharide Assembly

Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
3.9K
Protein Glycosylation01:25

Protein Glycosylation

Glycosylation, the most common post-translational modification for proteins, serves diverse functions. Adding sugars to proteins makes the proteins more resistant to proteolytic digestion. Glycosylated proteins can act as markers and receptors to promote cell-cell adhesion. Additionally, they have many essential quality control functions in the cell, such as correct protein folding and facilitating transport of misfolded proteins to the cytosol, which can be degraded.
Glycosylation occurs in...
10.7K